Overview: NGS 4H Syndrome Sequencing TestIntroduction: The NGS 4H Syndrome Sequencing Test sequences genes to diagnose 4H syndrome, causing ataxia or hypomyelination. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected 4H syndrome (hypomyelination, hypodontia, hypogonadotropic hypogonadism).
Other Names: 4H Syndrome Assay, POLR3-Related Leukodystrophy Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: 4H syndrome sequencing began in the 2000s with leukodystrophy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose 4H syndrome, guides treatment, and evaluates patients with ataxia or hypomyelination.
Test Parameters: 1. 4H Syndrome Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of ataxia, hypomyelination, or developmental delays.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document ataxia, hypomyelination, hypodontia, or family history of leukodystrophies. Include current medications, especially anticonvulsants.
Consent: Written consent required, detailing the tests purpose, 4H syndrome implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze 4H syndrome genes (e.g., POLR3A, POLR3B). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for 4H syndrome diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm 4H syndrome, guiding supportive care or genetic counseling. Negative results may require broader sequencing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, dental evaluation, or endocrine testing to confirm 4H syndrome diagnosis.
Test Limitations: Not all 4H syndrome cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Leukodystrophy Guidelines, 2023; Neurology, Wolf NI, 2022.
